血清midkine检测在非小细胞肺癌辅助诊断及预后评估中的价值

Detection of serum midkine in patients with non-small cell lung cancer and its clinical significance

目的探讨血清中期因子(S—MK)检测对非小细胞肺癌(NSCLC)辅助诊断的价值。方法选择NSCLC患者120例(观察组),同期因肺部良性肿瘤住院的患者62例(肺良性肿瘤组)及健康对照组64例,采用ELISA法测定观察组患者术前及术后(S—MK)水平,以及肺良性肿瘤组和健康对照组的S—MK水平。结果 NSCLC组(术前)S—MK水平为(285.70士20.52)pg/ml,高于肺良性肿瘤组(211.88±15.69)pg/m l和健康对照组(189.06士12.92)pg/ml(t=2.402、3.257,均P<0.01)。NSCLC组(术后1个月时)S—MK水平(218.26±10.77)Pg/ml,低于术前(285.70±20.52)pg/ml,差异有统计学意义(t=3.303,P<0.01)。结论 NSCLC患者S—MK水平升高,且术后出现一定程度的下降,S—MK水平可作为一种临床肿瘤标志物,为NSCLC的诊断、疗效评价提供一定的依据。

Objective TO detect serum midkine （S-MK） in patients with non-small cell lung cancer （NSCLC） and to evaluate its clinical significance. Methods The S-MK values were measured by enzyme-linked immunosorbent assay （ELISA） in 64 healthy controls, 62 patients with benign lung disease（LBD）, and 120 patients with NSCLC before surgery. The S-MK values were re-examined in NSCLC patients 1 month after surgery. Results The S-MK values in patients with NSCLC were significantly higher than those in patients with LBD or healthy controls （285.70 ± 20.52pg/ml vs. 211.88 ± 15.69pg/ml or 189.06 ± 12.92, P〈0.01）. S-MK significantly decreased in NSCLC patients 1month after surgery（218.26 ± 10.77 pg/ml, P〈0.01）. Conclu- sion The S-MK may be a useful serologic tumor biomarker for diagnosis and prognosis of NSCLC.